The National Institutes of Health announced today that the agency has added up to 4 million doses of the first of its vaccines for meningititis, Agrobacterium vaccae var.
fowleri, to the public health stockpile.
The vaccines are the first to be made available to the general public in the U.S. since the agency approved the first vaccination for menorrhagic fever in 2012.
“These vaccines will help keep Americans safe, but they will also save lives,” NIH Director Dr. Francis Collins said in a statement.
“With more than 4 million vaccines to date, the National Institutes is in the midst of an unprecedented effort to make our vaccines as safe as possible.
Today’s announcement will allow the world to enjoy the benefits of our new vaccines and will give us a critical boost in our efforts to ensure that Americans have access to the vaccines they need to protect themselves and their families.”
The new vaccines are available to people who are eligible for the three-dose series of vaccine, which is administered through a nasal spray, intramuscular injection, or other method.
As a general rule, vaccine recipients should get vaccinated no earlier than six weeks after the last dose.
However, people who have missed doses or have been hospitalized may need to wait longer to receive the first dose.
The first vaccine series is scheduled to be administered in 2018, and the next is scheduled for 2020.